USP 795 y 797 Guía de documentación de péptidos

¿Qué PVU? 795 y 797 La documentación de péptidos realmente decide

Los capítulos clasifican la preparación., no la molécula. USP 795 y 797 Las preguntas sobre la documentación de péptidos activan un desencadenante.: si la preparación terminada debe ser estéril en el momento de la administración. Esa única condición, ni la pureza del péptido ni su nivel de precios, decide qué capítulo rige el registro que se espera que tenga.

Las rutas estériles se encuentran debajo <797>. Inyecciones, aditivos intravenosos, oftálmicos, preparaciones intratecales, y los preparados para cavidades corporales que no se comunican con el entorno exterior caen todos en ese lado de la línea. Formas de dosificación no estériles, incluyendo líquidos orales, cápsulas, cremas, geles, y supositorios, incluirse en <795> (NCPA, Estándares de compuestos USP <795> y <797> presentación, 2026).

El límite tiene una segunda arista que pilla por sorpresa a los promotores. Un producto estéril fabricado de manera convencional y preparado estrictamente de acuerdo con el etiquetado aprobado por el fabricante se describe como fuera del alcance de <797>. Reconstituir un producto no estéril fabricado convencionalmente según su etiqueta para un paciente individual, sin guardarlo para uso futuro, no está compuesto bajo <795> (Junta de Farmacia de Mississippi, <797> Documento de preguntas frecuentes, 2023).

Clasificar erróneamente una compra es lo que convierte una pregunta rutinaria sobre calidad en una escalada. Si se equivoca en la categoría en el momento del pedido, todas las solicitudes de documentos posteriores llegarán con el estándar equivocado..

Suministro de grado de investigación, Apoyo al desarrollo, y uso relacionado con compuestos: Dibujando la línea

La categoría a la que pertenece un péptido está determinada por su uso previsto y su etiquetado., no por lo limpio que se ve su cromatograma. Existe una cadena de suministro de péptidos de grado de investigación para respaldar el trabajo de laboratorio y de desarrollo.: El material está etiquetado para uso exclusivo en investigación., y ese etiquetado es el que establece su estatus. Un certificado de análisis de lote que muestra la identidad y pureza mediante HPLC y espectrometría de masas documenta el material en sí.. no lo hace, por sí solo, hacer que ese material sea permisible para la composición.

Esa distinción es importante porque la vía de la capitalización tiene sus propias condiciones de entrada., y difieren entre los dos marcos.

Bajo la sección 503A, una sustancia farmacéutica a granel puede usarse solo si cumple con una monografía USP o NF aplicable y el capítulo de la USP sobre compuestos farmacéuticos., o es un componente de un medicamento aprobado por la FDA donde no existe una monografía, o aparece en la lista de productos a granel 503A (FDA, Sustancias farmacológicas a granel utilizadas en compuestos según la sección 503A, contenido actual a partir de 2026-05-14). Estas son alternativas, no es una lista de verificación para satisfacer en secuencia. Por separado, la sustancia debe llegar con un certificado de análisis válido y debe haber sido fabricada por un establecimiento registrado ante la FDA en la sección 510 (FDA, contenido actual a partir de 2026-05-14).

Las instalaciones de subcontratación operan bajo una regla más estricta: una sustancia farmacéutica a granel puede usarse solo si aparece en la lista de cantidades masivas 503B o se usa para componer un medicamento en la lista de escasez de medicamentos de la FDA en el momento de la composición., distribución, y dispensando (FDA, Sustancias farmacológicas a granel utilizadas en compuestos, contenido actual a partir de 2026-03-26).

El error recurrente es tratar una cifra de pureza como una mejora de categoría.. Un resultado de HPLC ≥98% describe el lote, no su postura regulatoria.

El conjunto de documentación: Lo que realmente contiene un expediente defendible

Un registro defendible no es una carpeta de certificados. It is a set of artifacts where each one proves a specific obligation, and a reviewer can trace the chain from supplier lot to internal use lot without asking you a question.

El FDA guidance to compounders on knowing bulk suppliers frames the obligations directly: source API from FDA-registered facilities, hold valid certificates of analysis, and know what testing the supplier actually performs. Those three obligations map onto distinct records.

The chain-of-custody handoff is the artifact most often missing. Without it, a supplier lot number and an internal use lot number sit in separate systems with no recorded link, and a reviewer cannot confirm that the material in the vial is the material the COA describes.

Advertencia: The record that matters most is the one written when the numbers do not match. A discrepancy between in-house verification and the supplier COA, and the investigation that followed, is the document a quality reviewer will ask for first.

Pruebas de identidad: Confirmando la molécula, No sólo la misa

Identity testing is a separate control from purity, and a single intact-mass figure does not establish it. A mass that matches the expected molecular weight tells you something is present at that mass. It does not tell you the sequence is correct, that the counterion is what the label claims, or that the material is free of the non-peptide components that sit outside the peptide-related impurity thresholds.

Servicios El EMA guideline on development and manufacture of synthetic peptides draws that boundary explicitly. Impurities in synthetic peptides are grouped as peptide-related (truncamientos, eliminaciones, oxidación, desamidación, sequence variants) and non-peptide (contraiones, residual solvents and reagents such as TFA). Counterion identity and content, AGT residuales, and water content are separate control items, not part of the peptide-related impurity thresholds. A peptide identity testing package that reports only the peptide-related side leaves three control items unaddressed.

Method conditions are what make an identity result evaluable. Yo Q2(R2) frames validation around specificity/selectivity, range, exactitud, and precision, with typical minimum experimental designs of 9 determinations across at least 3 concentration levels for accuracy and 9 determinations over 3 levels or 6 determinations at 100% of test concentration for precision. When assay and impurity share one test, the calibration range runs from the impurity reporting level up to 120% of the assay acceptance criterion.

So what does this mean for a supplier COA? An MS confirmation reported without method conditions cannot be evaluated. You cannot tell whether the method was specific to the sequence, what concentration levels were run, or whether the counterion was measured at all.

Evaluación de pureza: Leer el número detrás del porcentaje

A purity percentage without method conditions, a chromatogram, and impurity context is not evaluable. “≥98%” from two suppliers can describe two different measurements, and peptide purity evaluation starts by asking what the number is measuring.

The threshold scale and the advertising scale are not the same scale. Under the Ph. euros. general monograph “Substances for Pharmaceutical Use” referenced by the EMA guideline on the development and manufacture of synthetic peptides, peptide-related impurities are reported above 0.1%, identified above 0.5%, and qualified above 1.0%. Those are actions a manufacturer must take as impurity levels rise. A ≥98% HPLC figure is a headline result from one run, on one column, under one set of method conditions.

Typical reported COA practice for lyophilized synthetic peptides clusters around HPLC purity tiers of ≥95%, ≥98%, and ≥99%, intact-mass identity within about ±0.5 Da (or under 5 ppm on high-resolution instruments), water content roughly ≤5–8% by Karl Fischer, and retest or expiry windows of 12–24 months at −20 °C, como se describe en supplier COA-reading guides. These are industry-typical values that vary by supplier. They are not acceptance criteria, and treating them as such is the pitfall: a single percentage read as a purity specification.

Calificación del proveedor: Puntuación de la evidencia, No la reputación

Peptide supplier qualification is an evidence-scoring exercise, not a reputation check. The criteria are the same ones the earlier sections defined: identidad, pureza, method conditions, lot linkage, y control de cambios. Score each supplier against those criteria and the choice becomes defensible on paper.

Three supplier-side errors recur. A COA arrives without method conditions, so the purity figure cannot be reproduced. A certificate of origin arrives without lot linkage, so the material cannot be traced to the site that made it. A change-notification clause is absent from the agreement, so a specification change reaches the buyer after the fact.

FDA’s guidance to compounders on knowing your bulk suppliers and its conditions for 503A bulk drug substances both point the same direction: the buyer carries the burden of establishing that the source is acceptable and reliable, a responsibility USP <795> assigns to the designated person. That is the standard to score against.

Avanzado: Cuando la verificación interna no está de acuerdo con el COA del proveedor

If you already run in-house verification, this is the record that decides whether the disagreement is a supplier problem or a method problem. The distinction matters because the two failures route to different owners, and treating a method problem as a supplier problem burns a relationship you may need later.

Re-check method conditions and system suitability before you re-test the lot. Column chemistry, mobile phase composition, gradiente, and detector settings all shift results, and a system suitability failure invalidates the run regardless of what the sample contains. Only after your system passes should you re-inject the lot.

Then compare your method against the supplier’s stated method. The ICH Q2(R2) guideline frames validation around specificity, exactitud, precisión, and range, so if your method and the supplier’s differ on any of those characteristics, the two numbers are not measuring the same thing. Counterion identity and content, AGT residuales, and water content are separate control items, and a gap in any of them can explain a purity delta without either party being wrong.

Document the discrepancy with both data sets attached, then route the outcome through your designated person.

The caution is a prerequisite, not a comment on your competence: this sequence only resolves a disagreement if your own method carries documented validation and a defined acceptance criterion. Without those two things, you have two uncalibrated numbers and no basis for deciding which one to trust.

Empezando: Los primeros tres movimientos

The lowest-friction first action is not writing a new SOP. It is classifying every peptide lot you already hold, because the classification determines which documentation obligations apply at all. A lot that lands in the research-grade category carries a different evidence burden than one headed toward compounding-related use, and you cannot know which records are missing until each lot has a category.

Paso 1: Classify the inventory. Run every existing lot through the classification table and mark its category. This is a desk exercise. It needs no supplier contact, no legal review, and no new template.

Paso 2: Assemble what exists. For each lot in the compounding-related category, pull the certificate of analysis, the certificate of origin, and the lot linkage into one location, then mark what is absent. Missing items are findings, not failures. You are building the gap list that tells you where to spend effort.

Paso 3: Score your suppliers. Take your top two or three suppliers through the qualification matrix, and open a change-notification conversation with any that score weakly. Suppliers who cannot answer a notification question in writing are telling you something useful before a quality question escalates.

The hesitation worth naming directly: this is not a compliance project that requires legal sign-off before it can begin. Classification and evidence-gathering are internal, reversible, and produce no external commitment. Start with the inventory, and let the gaps tell you what USP 795 y 797 peptide documentation work actually remains.

Preguntas frecuentes

What does the difference between USP <795> y <797> mean for a peptide purchase?

It decides which documentation standard your record has to satisfy, not which supplier you buy from. USP <795> governs nonsterile compounded preparations and USP <797> governs sterile ones, so the same peptide can sit under either chapter depending on the physical form and handling route it is destined for. Buyers should confirm the intended use category first, because that choice determines the identity, pureza, and handling evidence the record must carry. Producción de péptidos

¿Se puede utilizar un péptido de grado de investigación con un COA ≥98% como ingrediente compuesto??

No. A ≥98% purity figure describes the material’s assay result, not its suitability for a preparation, and research-grade supply is not manufactured or documented against compounding standards. The advertised percentage also says nothing about which impurities were detected, how they were identified, or whether they were qualified against a limit. Treat the research-grade label as a supply category, not as a compliance status.

¿Qué debe contener un certificado de análisis válido??

A defensible COA names the specific lot, the analytical method used for each test, the acceptance criterion, and the measured result, so a reviewer can trace the number back to the method that produced it. A document that reports a single purity percentage with no method conditions, no lot identifier, and no raw output is a summary, not evidence. The record should also state who performed the testing and when.

¿Las pruebas de identidad y las pruebas de pureza son la misma prueba??

No. Identity testing confirms the molecule is what the label says it is; purity testing measures how much of everything else is present. A sample can pass an identity check and still fail on impurity profile, which is why the two belong in separate rows of the documentation set rather than collapsed into one line.

¿Con qué frecuencia se debe repetir la calificación del proveedor??

Requalification should be triggered by change, not by the calendar alone. A new lot, a revised method, a relocated manufacturing site, or a change in the supplier’s own specification all warrant a fresh review of the evidence. A periodic re-check adds value mainly as a backstop for suppliers whose change notifications are unreliable.

¿Una etiqueta RUO por sí sola resuelve la cuestión??

No. The research-use-only designation limits the claims a supplier can make about the material; it does not by itself establish or exclude anything about the buyer’s intended use. What settles the question is the documented chain from the material’s stated grade through to the use category the buyer has already identified.

¿Cómo se informan las impurezas?, identificación, y los umbrales de calificación difieren de los niveles de pureza anunciados?

They answer different questions. Reporting thresholds set the level at which an impurity must appear in the record at all; identification thresholds set the level at which its structure must be determined; qualification thresholds set the level at which it must be shown to be safe at the intended exposure. An advertised purity tier is a single headline number and carries none of that structure, which is why a high percentage and a clean impurity profile are not interchangeable claims.

Conclusión

USP 795 y 797 peptide documentation is decided by the preparation and its intended use, not by the paperwork you assemble afterward: the category comes first, and every record you keep has to answer to it. That is the spine this guide has followed throughout. You draw the line between research-grade supply, development support, and compounding-related use. You build a record set that can survive a question. You confirm the molecule by identity testing rather than by mass alone, you read the purity percentage against the method that produced it, and you score supplier evidence on what it actually shows instead of on reputation. When in-house verification disagrees with a supplier COA, the disagreement itself is information, and it belongs in the file.

What moves is the enforcement posture, not the compendial requirements. Inspection attention, documentation expectations, and the questions buyers ask tend to shift faster than the standards they are built on, so a record set that is defensible today is the one that stays defensible when the scrutiny changes. Build for the requirement, not for the current mood.

This article is an educational overview. It is not legal, regulatory, or compliance advice, and it does not describe compounding services or compounded preparations. Consult qualified regulatory counsel or a licensed pharmacist for determinations about your own operations. MOL Changes operates in the peptide and life-sciences supply space, so treat this as a neutral commercial-interest disclosure rather than an independent assessment.

Próximos pasos

If you want to compare your current documentation set against the five-part framework above, request the analytical documentation package or speak with a technical specialist about the records that accompany your materials.